Since the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to spread worldwide and has become a major global public health threat. SARS-CoV-2 has the characteristics of a long in...Since the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to spread worldwide and has become a major global public health threat. SARS-CoV-2 has the characteristics of a long incubation period and asymptomatic infection, which are undoubtedly major challenges to blood transfusion safety. Although no research has suggested that there is a risk of SARS-CoV-2 transmission through blood transfusion, the safe use of clinical blood during the epidemic is a serious problem faced by blood collection and supply institutions. Herein, we elaborate on the management of blood collection and supply during the coronavirus disease 2019 (COVID-19) pandemic from aspects such as blood inventory management, clinical blood use, and reducing the risk of transmission of SARS-CoV-2 via blood transfusion. Blood service departments should adopt flexible policies to ensure that blood collection networks can meet clinical needs, while at the same time protecting staff and blood donors, maintaining blood safety, and reducing blood risks during the epidemic.展开更多
目的 了解美国军队野战输血医学发展的主要方向和最新动态。方法 通过www.clinicaltrials.gov网站首页,以“United States Department of Defense”“U.S.Army Medical Research and Development Command”“United States Naval Medica...目的 了解美国军队野战输血医学发展的主要方向和最新动态。方法 通过www.clinicaltrials.gov网站首页,以“United States Department of Defense”“U.S.Army Medical Research and Development Command”“United States Naval Medical Research Center”为检索词,检索自ClinicalTrials.gov成立(2002年)起至2021年5月1日野战输血医学相关临床试验项目的完整备案信息,通过研究进展状态、临床分期、任务分配、地域分布和主要研究内容及研究成果等,分析其主要特点。结果 共检索到临床试验项目931项,与野战输血医学密切相关的有16项;其中全血病原体处置占25%(4/16)、血小板输注占25%(4/16)、血浆输注占25%(4/16)、全血输注占18.75(3/16)和其他类型研究占6.25%(1/16)。美国军方注重在血液安全、血液贮存等方面的新技术突破,在抗休克输血输液治疗方面的效果评价,在全血早期输注治疗方面的应用探索和在血液保障技术产品研发方面的军地互动优势。结论 基于ClinicalTrials.gov对美国军方野战输血医学的分析,有利于快速了解美国军队野战输血医学的发展现状和趋势。展开更多
The aim was to investigate whether using a removing blood stasis method in hyperacute intracranial hemorrhage stage can lead to hematoma enlargement and its clinical efficacy.A multicenter retrospective randomized dou...The aim was to investigate whether using a removing blood stasis method in hyperacute intracranial hemorrhage stage can lead to hematoma enlargement and its clinical efficacy.A multicenter retrospective randomized double-blind placebo-controlled clinical study.We recruited patients aged 18 years or older and presenting at less than 6 h from symptom onset in 8 research centers.All the patients展开更多
文摘Since the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to spread worldwide and has become a major global public health threat. SARS-CoV-2 has the characteristics of a long incubation period and asymptomatic infection, which are undoubtedly major challenges to blood transfusion safety. Although no research has suggested that there is a risk of SARS-CoV-2 transmission through blood transfusion, the safe use of clinical blood during the epidemic is a serious problem faced by blood collection and supply institutions. Herein, we elaborate on the management of blood collection and supply during the coronavirus disease 2019 (COVID-19) pandemic from aspects such as blood inventory management, clinical blood use, and reducing the risk of transmission of SARS-CoV-2 via blood transfusion. Blood service departments should adopt flexible policies to ensure that blood collection networks can meet clinical needs, while at the same time protecting staff and blood donors, maintaining blood safety, and reducing blood risks during the epidemic.
文摘目的 了解美国军队野战输血医学发展的主要方向和最新动态。方法 通过www.clinicaltrials.gov网站首页,以“United States Department of Defense”“U.S.Army Medical Research and Development Command”“United States Naval Medical Research Center”为检索词,检索自ClinicalTrials.gov成立(2002年)起至2021年5月1日野战输血医学相关临床试验项目的完整备案信息,通过研究进展状态、临床分期、任务分配、地域分布和主要研究内容及研究成果等,分析其主要特点。结果 共检索到临床试验项目931项,与野战输血医学密切相关的有16项;其中全血病原体处置占25%(4/16)、血小板输注占25%(4/16)、血浆输注占25%(4/16)、全血输注占18.75(3/16)和其他类型研究占6.25%(1/16)。美国军方注重在血液安全、血液贮存等方面的新技术突破,在抗休克输血输液治疗方面的效果评价,在全血早期输注治疗方面的应用探索和在血液保障技术产品研发方面的军地互动优势。结论 基于ClinicalTrials.gov对美国军方野战输血医学的分析,有利于快速了解美国军队野战输血医学的发展现状和趋势。
文摘The aim was to investigate whether using a removing blood stasis method in hyperacute intracranial hemorrhage stage can lead to hematoma enlargement and its clinical efficacy.A multicenter retrospective randomized double-blind placebo-controlled clinical study.We recruited patients aged 18 years or older and presenting at less than 6 h from symptom onset in 8 research centers.All the patients
